Economic burden of hypoglycemia in patients with Type 2 diabetes

School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, New Orleans, LA 70112, USA.
Expert Review of Pharmacoeconomics & Outcomes Research (Impact Factor: 1.67). 02/2012; 12(1):47-51. DOI: 10.1586/erp.11.87
Source: PubMed


Hypoglycemia is an acute complication of diabetes that increases morbidity, mortality and economic costs of diabetes. It presents major clinical problems for the management of Type 2 diabetes as this disease represents the great majority of all diabetes cases. Hypoglycemia makes it difficult for some individuals to achieve good glycemic control, reduces quality of life and increases the burden of diabetes to healthcare systems. Understanding hypoglycemia risk factors can help patients with Type 2 diabetes to correct and avoid hypoglycemia. Recently, an increased risk of hypoglycemia with intensive glycemic control has been identified as an important problem in optimally controlling blood glucose levels in patients with Type 2 diabetes.

Download full-text


Available from: Yingnan Zhao, Oct 13, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The American Association of Clinical Endocrinologists/American College of Endocrinology Medical Guidelines for Clinical Practice are systematically developed statements to assist healthcare professionals in medical decision making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. A1C = hemoglobin A1c AACE = American Association of Clinical Endocrinologists ACCORD = Action to Control Cardiovascular Risk in Diabetes ACE = angiotensin-converting enzyme ADA = American Diabetes Association ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation AER = albumin excretion rate ApoB = apolipoprotein B ARB = angiotensin II receptor blocker ASCVD = atherosclerotic cardiovascular disease BEL = best evidence level BMI = body mass index CDC = Centers for Disease Control and Prevention CDE = certified diabetes educator CGM = continuous glucose monitoring CKD = chronic kidney disease CPAP = continuous positive airway pressure CPG = clinical practice guideline CSI = continuous subcutaneous insulin infusion CVD = cardiovascular disease DCCT = Diabetes Control and Complications DKA = diabetic ketoacidosis DM = diabetes mellitus DPP = Diabetes Prevention Program DPP-4 = dipeptidyl peptidase 4 DSME = diabetes self-management education DSPN = distal symmetric polyneuropathy EL = evidence level ESRD = end-stage renal disease FDA = U.S. Food and Drug Administration FPG = fasting plasma glucose GDM = gestational diabetes mellitus GFR = glomerular filtration rate GI = gastrointestinal GLP-1 = glucagon-like peptide 1 HBV = hepatitis B virus HDL-C = high-density lipoprotein cholesterol HR = hazard ratio ICU = intensive care unit IFG = impaired fasting glucose IGT = impaired glucose tolerance ISF = insulin sensitivity factor LDL-C = low-density lipoprotein cholesterol LDL-P = low-density lipoprotein particles Look AHEAD = Look Action for Health in Diabetes MDI = multiple daily injections MNT = medical nutrition therapy NPH = neutral protamine Hagedorn OGTT = oral glucose tolerance test OSA = obstructive sleep apnea PG = plasma glucose POC = point-of-care PPG = postprandial glucose PTH = parathyroid hormone Q = clinical question R = recommendation RAAS = reninangiotensin-aldosterone system RCT = randomized controlled trial SFN = small-fiber neuropathy SGLT2 = sodium glucose cotransporter 2 SMBG = self-monitoring of blood glucose T1D = type 1 diabetes T2D = type 2 diabetes TZD = thiazolidinedione UKPDS = United Kingdom Prospective Diabetes Study VADT = Veterans Affairs Diabetes Trial.
    Endocrine Practice 03/2011; 17 Suppl 2:1-53. DOI:10.4158/EP.17.S2.1 · 2.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adding glucagon-like peptide-1 (GLP-1) receptor agonists to insulin therapy for patients with type 2 diabetes mellitus (T2DM): why and how patients with T2DM who progress to insulin therapy usually do so by starting with a single injection of a long-acting insulin analog, added to oral anti-diabetic drugs. Long-acting insulin analogs provide basal insulin coverage and address elevated fasting blood glucose levels. Because of the near universal efficacy of insulin, such approaches are almost always successful in lowering blood glucose levels, but may not bring patients to goal because they do not address postprandial hyperglycemia. The approach to postprandial hyperglycemia has typically been to add doses of rapid-acting insulin analogs before meals. However, this may increase the risk of hypoglycemia and weight gain, and may not be acceptable to patients both in terms of patient tolerability and adherence. New approaches include the addition of GLP-1 receptor agonists to insulin in patients with uncontrolled T2DM. This article reviews the data and the clinical context of such action with respect to issues of glycemic efficacy, patient tolerability, and safety.
    Osteopathic Family Physician 01/2013; 5(1):51–57. DOI:10.1016/j.osfp.2012.11.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To review and discuss the risks and impact of hypoglycemia and provide guidance for the prevention of hypoglycemia in type 2 diabetes (T2DM).Methods: We review and discuss the risks and impact of hypoglycemia, providing specific guidance regarding the prevention of hypoglycemia and judicial selection of glucose-lowering agents in individuals with T2DM.Results: Hypoglycemia in type 2 diabetes (T2DM) is under-recognized and under-reported. Emerging evidence from large clinical trials suggest that hypoglycemia may be an important risk factor for morbidity and mortality in T2DM. In addition, hypoglycemia is associated with poorer quality of life, greater healthcare utilization costs, and poor adherence to medical regiments.Conclusion: These findings have led professional organizations to emphasize the prevention of hypoglycemia as an important consideration when initiating or intensifying treatment regimens. In clinical settings, particular attention should be paid to a patient's risk for hypoglycemia when initiating or intensifying the pharmacological treatment regimen. Furthermore, the endocrinologist can play an important role in educating not only the patient, but also other members of the diabetes-management team regarding the need for individualized therapy.
    Endocrine Practice 02/2013; 19(3):1-33. DOI:10.4158/EP13005.RA · 2.81 Impact Factor
Show more